Trump signs order to speed FDA review of psychedelic drugs, citing veterans & PTSD

President Donald Trump signed an executive order to accelerate the FDA review of certain psychedelic drugs designated as 'breakthrough therapies'. The order aims to fast-track treatments for conditions like PTSD, depression, and other mental health disorders. The FDA's 'breakthrough therapy' designation is for drugs showing substantial improvement over existing treatments. Supporters believe this move could expand access to potentially life-changing treatments for veterans and others struggling with mental health issues. Critics caution that accelerating the approval process may raise concerns about safety and oversight. The order instructs the FDA to prioritize applications for these therapies, potentially shortening their timeline to reach patients.